December 2018 - Clinical trial listings - geography, conditions, companies -

Clinical Trials for Ziprasidone Hydrochloride

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00014001	CATIE- Schizophrenia Trial	Completed	National Institute of Mental Health (NIMH)	Phase 4	The CATIE Schizophrenia Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The schizophrenia trial is being conducted to determine the long-term effects and usefulness of antipsychotic medications in persons with schizophrenia. It is designed for people with schizophrenia who may benefit from a medication change. The study involves the newer atypical antipsychotics (olanzapine, quetiapine, risperidone, clozapine, and ziprasidone)and the typical antipsychotics (perphenazine and fluphenazine decanoate). All participants will receive an initial comprehensive medical and psychiatric evaluation and will be closely followed throughout the study. For most participants the study will last up to 18 months. Everyone in the study will be offered an educational program about schizophrenia and family members will be encouraged to participate.
NCT00034801	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia	Completed	Eli Lilly and Company	Phase 4	This is a research study comparing the safety and efficacy of two active study medications
NCT00044655	Switching Medication to Treat Schizophrenia	Completed	National Institute of Mental Health (NIMH)	Phase 4	This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
NCT00044655	Switching Medication to Treat Schizophrenia	Completed	Icahn School of Medicine at Mount Sinai	Phase 4	This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
NCT00048802	Treatment and Outcome of Early Onset Bipolar Disorder	Completed	National Institute of Mental Health (NIMH)	Phase 4	This study will compare the effectiveness in the maintenance of continuing adjunctive atypical antipsychotic medication compared to traditional mood stabilizer(s) alone in the maintenance treatment of adolescents with bipolar disorder.
NCT00048802	Treatment and Outcome of Early Onset Bipolar Disorder	Completed	Northwell Health	Phase 4	This study will compare the effectiveness in the maintenance of continuing adjunctive atypical antipsychotic medication compared to traditional mood stabilizer(s) alone in the maintenance treatment of adolescents with bipolar disorder.
Trial ID	Title	Status	Sponsor	Phase	Summary